癌症免疫检查点抑制剂治疗期间的非结核分枝杆菌感染：一项系统综述
Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review.
作者信息
Lombardi Andrea, Gramegna Andrea, Ori Margherita, Azzarà Cecilia, Blasi Francesco, Gori Andrea
机构信息
Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
出版信息
ERJ Open Res. 2022 Nov 28;8(4). doi: 10.1183/23120541.00364-2022. eCollection 2022 Oct.
Abstract
Immune checkpoint inhibitors (ICIs) are drugs growingly employed in the treatment of cancers, but there are still uncertainties about their possible role in the risk of developing nontuberculous mycobacteria (NTM) infections. To understand this, we performed a systematic review of the literature including studies published between 20 June 2012 and 20 June 2022 which described the occurrence of NTM infections among patients treated with ICIs. Overall, we included seven studies describing nine patients with NTM infection occurring during ICIs therapy. NTM infections occurring during ICIs therapy are mainly caused by germs belonging to the , involve primarily the lungs, on average 1 year after the start of treatment, and are not associated with immunosuppressive treatments.
摘要
免疫检查点抑制剂（ICIs）是越来越多地用于治疗癌症的药物，但它们在非结核分枝杆菌（NTM）感染风险中可能发挥的作用仍存在不确定性。为了解这一点，我们对2012年6月20日至2022年6月20日期间发表的文献进行了系统综述，这些文献描述了接受ICIs治疗的患者中NTM感染的发生情况。总体而言，我们纳入了七项研究，描述了9例在ICIs治疗期间发生NTM感染的患者。ICIs治疗期间发生的NTM感染主要由属于[此处原文缺失相关菌群信息]的细菌引起，主要累及肺部，平均在治疗开始后1年，且与免疫抑制治疗无关。
相似文献
1
Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review.癌症免疫检查点抑制剂治疗期间的非结核分枝杆菌感染：一项系统综述
ERJ Open Res. 2022 Nov 28;8(4). doi: 10.1183/23120541.00364-2022. eCollection 2022 Oct.
2
Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?免疫检查点抑制剂治疗肺腺癌后 67 岁男性患奇异分枝杆菌肺病：免疫失调引起的感染？
BMC Infect Dis. 2023 Sep 4;23(1):573. doi: 10.1186/s12879-023-08537-w.
3
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?关于使用免疫检查点抑制剂引发分枝杆菌感染风险争议的叙述性综述：金发姑娘知道答案吗？
J Thorac Dis. 2024 Feb 29;16(2):1601-1624. doi: 10.21037/jtd-23-1395. Epub 2024 Feb 27.
4
Prevalence of Nontuberculous Mycobacterium Infections versus Tuberculosis among Autopsied HIV Patients in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.撒哈拉以南非洲地区尸检 HIV 患者中非结核分枝杆菌感染与结核病的流行率：系统评价和荟萃分析。
Am J Trop Med Hyg. 2020 Nov 23;104(2):628-633. doi: 10.4269/ajtmh.20-0973.
5
Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.非结核分枝杆菌肺病由鸟分枝杆菌复合群和脓肿分枝杆菌复合群混合感染引起。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01105-18. Print 2018 Oct.
6
Nontuberculous mycobacterial infection in a tertiary care center in Mexico, 2001-2017.2001-2017 年墨西哥一家三级保健中心的非结核分枝杆菌感染。
Braz J Infect Dis. 2020 May-Jun;24(3):213-220. doi: 10.1016/j.bjid.2020.04.012. Epub 2020 May 16.
7
Nontuberculous mycobacterial lung disease epidemiology in Taiwan: A systematic review.台湾地区非结核分枝杆菌肺病的流行病学：一项系统评价。
J Formos Med Assoc. 2020 Jun;119 Suppl 1:S4-S12. doi: 10.1016/j.jfma.2020.05.019. Epub 2020 May 30.
8
Nontuberculosis mycobacterial infections at a specialized tuberculosis treatment centre in the Republic of Korea.韩国一家专业结核病治疗中心的非结核分枝杆菌感染情况。
BMC Infect Dis. 2017 Jun 15;17(1):432. doi: 10.1186/s12879-017-2532-4.
9
Development of Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗的肺癌患者复杂肺部疾病的发生
Open Forum Infect Dis. 2020 Mar 7;7(3):ofaa067. doi: 10.1093/ofid/ofaa067. eCollection 2020 Mar.
10
A Global Survey of Mycobacterial Diversity in Soil.土壤中分枝杆菌多样性的全球调查。
Appl Environ Microbiol. 2019 Aug 14;85(17). doi: 10.1128/AEM.01180-19. Print 2019 Sep 1.
引用本文的文献
1
Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors.基于人群的免疫检查点抑制剂相关分枝杆菌感染风险分析。
Clin Infect Dis. 2025 Aug 1;81(1):176-178. doi: 10.1093/cid/ciae626.
2
Growing from common ground: nontuberculous mycobacteria and bronchiectasis.从共同基础发展而来：非结核分枝杆菌与支气管扩张症。
Eur Respir Rev. 2024 Jul 3;33(173). doi: 10.1183/16000617.0058-2024. Print 2024 Jul.
3
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?关于使用免疫检查点抑制剂引发分枝杆菌感染风险争议的叙述性综述：金发姑娘知道答案吗？
J Thorac Dis. 2024 Feb 29;16(2):1601-1624. doi: 10.21037/jtd-23-1395. Epub 2024 Feb 27.
4
Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?免疫检查点抑制剂治疗肺腺癌后 67 岁男性患奇异分枝杆菌肺病：免疫失调引起的感染？
BMC Infect Dis. 2023 Sep 4;23(1):573. doi: 10.1186/s12879-023-08537-w.
5
Comments on "PD-1 Inhibitor for Disseminated Infection in a Person Living With HIV".关于“PD-1抑制剂用于一名HIV感染者的播散性感染”的评论
Open Forum Infect Dis. 2023 Feb 14;10(3):ofad083. doi: 10.1093/ofid/ofad083. eCollection 2023 Mar.
本文引用的文献
1
Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review.固有和适应性淋巴细胞在非结核分枝杆菌肺病中的作用：综述。
Front Immunol. 2022 Jun 28;13:927049. doi: 10.3389/fimmu.2022.927049. eCollection 2022.
2
Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study.肺癌患者接受免疫检查点抑制剂治疗时的序贯干扰素-γ释放试验：一项前瞻性队列研究。
Cancer Immunol Immunother. 2022 Nov;71(11):2757-2764. doi: 10.1007/s00262-022-03198-1. Epub 2022 Apr 16.
3
complex lung disease in a patient treated with an immune checkpoint inhibitor: A case report.接受免疫检查点抑制剂治疗的患者出现复杂性肺部疾病：一例报告。
Mol Clin Oncol. 2022 Feb;16(2):37. doi: 10.3892/mco.2021.2470. Epub 2021 Dec 17.
4
T-Cell Exhaustion in and Nontuberculous Mycobacteria Infection: Pathophysiology and Therapeutic Perspectives.结核与非结核分枝杆菌感染中的T细胞耗竭：病理生理学与治疗前景
Microorganisms. 2021 Nov 28;9(12):2460. doi: 10.3390/microorganisms9122460.
5
Exacerbation of nontuberculous mycobacterial pulmonary disease in a patient with advanced non-small-cell lung cancer during treatment with PD-1 inhibitor and chemotherapy.一名晚期非小细胞肺癌患者在接受PD-1抑制剂和化疗治疗期间非结核分枝杆菌肺病病情加重。
Respir Med Case Rep. 2021 Oct 21;34:101529. doi: 10.1016/j.rmcr.2021.101529. eCollection 2021.
6
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.免疫失调相关感染：癌症免疫治疗的一种新出现的并发症。
Thorax. 2022 Mar;77(3):304-311. doi: 10.1136/thoraxjnl-2021-217260. Epub 2021 Oct 4.
7
Vertebral osteomyelitis caused by Mycobacteroides abscessus subsp. abscessus resulting in spinal cord injury due to vertebral body fractures.脓肿分枝杆菌亚种脓肿导致的脊椎骨骨折并发脊椎骨感染。
J Infect Chemother. 2022 Feb;28(2):290-294. doi: 10.1016/j.jiac.2021.09.013. Epub 2021 Sep 28.
8
Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer.尼伏鲁单抗治疗转移性乳腺癌患者发生与装置相关的马格利特分枝杆菌感染。
Intern Med. 2021 Nov 1;60(21):3485-3488. doi: 10.2169/internalmedicine.6550-20. Epub 2021 May 14.
9
Cavitary Mycobacterium avium Complex Lung Disease Developed After Immunotherapy.免疫治疗后发生的空洞型鸟分枝杆菌复合群肺病
Arch Bronconeumol. 2022 Feb;58(2):174. doi: 10.1016/j.arbres.2021.04.014. Epub 2021 Apr 25.
10
Rapid development of pulmonary Mycobacterium avium infection during chemoradiotherapy followed by durvalumab treatment in a locally advanced NSCLC patient.一名局部晚期非小细胞肺癌患者在放化疗期间快速出现鸟分枝杆菌肺部感染，随后接受度伐利尤单抗治疗。
Lung Cancer. 2021 Mar;153:182-183. doi: 10.1016/j.lungcan.2021.01.021. Epub 2021 Jan 30.
Zotero 插件